Francoise Frerart
Overview
Explore the profile of Francoise Frerart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bukara K, Schueller L, Rosier J, Martens M, Daems T, Verheyden L, et al.
Eur J Pharm Biopharm
. 2016 Sep;
108:220-225.
PMID: 27648957
Formulating poorly water soluble drugs using ordered mesoporous silica materials is an emerging approach to tackle solubility-related bioavailability problems. The current study was conducted to assess the bioavailability-enhancing potential of...
2.
Sonveaux P, Copetti T, De Saedeleer C, Vegran F, Verrax J, Kennedy K, et al.
PLoS One
. 2012 Mar;
7(3):e33418.
PMID: 22428047
Switching to a glycolytic metabolism is a rapid adaptation of tumor cells to hypoxia. Although this metabolic conversion may primarily represent a rescue pathway to meet the bioenergetic and biosynthetic...
3.
Frerart F, Lobysheva I, Gallez B, Dessy C, Feron O
Mol Cancer Res
. 2009 Jul;
7(7):1056-63.
PMID: 19567781
The biological status of nitrite recently evolved from an inactive end product of nitric oxide (NO) metabolism to a major intravascular and tissue storage of NO. Several enzymes and proteins...
4.
Frerart F, Sonveaux P, Rath G, Smoos A, Meqor A, Charlier N, et al.
Clin Cancer Res
. 2008 May;
14(9):2768-74.
PMID: 18451244
Purpose: The biological status of nitrite recently evolved from an inactive end product of nitric oxide catabolism to the largest intravascular and tissue storage of nitric oxide (NO). Although low...
5.
Dewever J, Frerart F, Bouzin C, Baudelet C, Ansiaux R, Sonveaux P, et al.
Am J Pathol
. 2007 Oct;
171(5):1619-28.
PMID: 17916598
In the normal microvasculature, caveolin-1, the structural protein of caveolae, modulates transcytosis and paracellular permeability. Here, we used caveolin-1-deficient mice (Cav(-/-)) to track the potential active roles of caveolin-1 down-modulation...
6.
Sonveaux P, Frerart F, Bouzin C, Brouet A, Dewever J, Jordan B, et al.
Int J Radiat Oncol Biol Phys
. 2007 Feb;
67(4):1155-62.
PMID: 17276618
Purpose: To determine whether radiation-induced increases in nitric oxide (NO) production can influence tumor blood flow and improve delivery of Akt-targeting therapeutic DNA lipocomplexes to the tumor. Methods And Materials:...
7.
Jost M, Folgueras A, Frerart F, Pendas A, Blacher S, Houard X, et al.
Cancer Res
. 2006 May;
66(10):5234-41.
PMID: 16707448
Among matrix metalloproteinases (MMP), MMP-19 displays unique structural features and tissue distribution. In contrast to most MMPs, MMP-19 is expressed in normal human epidermis and down-regulated during malignant transformation and...
8.
Sbaa E, Dewever J, Martinive P, Bouzin C, Frerart F, Balligand J, et al.
Circ Res
. 2006 Apr;
98(9):1219-27.
PMID: 16601228
When neovascularization is triggered in ischemic tissues, angiogenesis but also (postnatal) vasculogenesis is induced, the latter requiring the mobilization of endothelial progenitor cells (EPC) from the bone marrow. Caveolin, the...
9.
Sbaa E, Frerart F, Feron O
Trends Cardiovasc Med
. 2005 Sep;
15(5):157-62.
PMID: 16165011
Caveolae are plasmalemmal invaginations formed by the sequestration of cholesterol and glycosphingolipids with self-associating molecules named caveolins, resulting in a platform for the assembly of signaling complexes at the surface...
10.
Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva I, Frerart F, et al.
Circulation
. 2005 Aug;
112(8):1198-205.
PMID: 16116070
Background: The therapeutic effects of nonspecific beta-blockers are limited by vasoconstriction, thus justifying the interest in molecules with ancillary vasodilating properties. Nebivolol is a selective beta1-adrenoreceptor antagonist that releases nitric...